STALLERGENES-GREER
27.5.2024 10:01:30 CEST | Business Wire | Press release
The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy. These awards recognise outstanding contributions to allergy research and environmental health initiatives and allocate up to €150,000 to support these efforts.
After thorough review of the 45 high-level applications by the Foundation’s Scientific Board and Managing Board, the following researchers have been selected as recipients:
Innovation Awards
- Rising Talent Category:
Assoc. Prof. Jennifer Koplin, Group Leader, Childhood Allergy & Epidemiology, Child Health Research Centre, The University of Queensland, Australia, recognised for her research: “Association between earlier introduction of peanut and prevalence of peanut allergy in infants in Australia” will receive €25,000.
Assoc. Prof. Rachel Peters, Principal Research Fellow, Murdoch Children's Research Institute, Australia, recognised for her research: “Multiple food allergy phenotypes in infancy are associated with lung function deficits and asthma at 6 years of age: a prospective cohort study in Australia” will receive €25,000.
- Mid-Career Scientist Category:
Assoc. Prof. Jenny Hallgren Martinsson, Senior Lecturer in Immunology, Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden, recognized for her research: “Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients” will receive €25,000.
Dr Luciana Kase Tanno, Researcher, University Hospital of Montpellier, France, recognised for her research: “Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases 11” will receive €25,000.
Environmental Health Award
Dr Dorra Gharbi, Post doctoral research fellow, Allergology and Immunology Unit, Lung Institute, University of Cape Town, South Africa, recognised for her research: “Allergenic tree pollen in Johannesburg and Cape Town as a public health risk: Towards a sustainable implementation framework for South African cities” will receive €50,000.
Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation, expresses his congratulations to the award recipients. “These researchers exemplify the spirit of innovation and dedication that the Stallergenes Greer Foundation seeks to promote. Their work not only advances our understanding of allergies but also brings us closer to creating healthier futures for all. These grants contribute to nurturing the next generation of researchers, in line with the foundation’s core mission of supporting academic endeavors aimed at fostering future leaders in allergy healthcare.”
The Scientific Committee, composed of a panel of international renowned experts:
- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France)
- Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, (Vatican City)
- Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon)
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)
highlighted the comprehensive coverage of allergy research of these awards, spanning public health with international classification of diseases, clinical science in asthma, and epidemiology in food allergy and aerobiology. The members also noted that these awards present an outstanding opportunity to highlight the importance of allergy research while tackling the increasing prevalence of allergic disease across the globe.
The Stallergenes Greer Foundation extends its gratitude to all applicants and acknowledges the invaluable contribution of the Scientific Board in the selection process.
The next Science Awards will be announced in 2025.
About the research projects
Jennifer Koplin’s research uses large-scale population-based studies to advance the understanding of childhood food allergy. These studies contribute to the development of novel prevention interventions and are helping to target emerging prevention and treatment strategies for the individuals who will benefit most from these interventions. Her innovative work with the EarlyNuts study evaluated the uptake and impact of early peanut introduction on peanut allergy, not only showing that population-level changes in infant feeding practices are possible, but also contributing to reshaping clinical and public health guidelines, and inspiring novel clinical trials internationally.
Soriano VX, et al: Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. JAMA. 2022 Jul 5;328(1):48-56. https://pubmed.ncbi.nlm.nih.gov/35788795/
Rachel Peters’ research aims to reduce the adverse consequences of infant food allergy – affecting up to 10% of children worldwide – on children’s future health. Through a pioneering study on the link between childhood food allergy and respiratory health, she uncovered that infants with food allergy, even if it resolves, present with lung function deficits and a higher risk of asthma by school age. These findings are sparking greater clinical vigilance regarding the monitoring of respiratory health of children with food allergies and will support clinicians worldwide in tailoring patient care.
Peters RL. Soriano VX, Lycett K, et al: Multiple food allergy phenotypes in infancy are associated with lung function deficits and asthma at 6 years of age: a prospective cohort study in Australia. The Lancet child & adolescent health 2023 Sep;7(9):636-647 .https://pubmed.ncbi.nlm.nih.gov/37506717/
Jenny Hallgren Martinsson’s research interest is to determine the role of mast cells—immune cells responsible for immediate allergic reactions—in allergic asthma. Her recent cutting-edge study on birch pollen-sensitized asthma patients and mast cell biology suggests that mast cell progenitors may play a pathogenic role in allergic asthma, thus paving the way for the development of new biomarkers and treatment targets for asthma.
P Abigail Alvarado-Vazquez et al, Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients Allergy. 2023 Nov;78(11):2959-2968. doi: 10.1111/all.15860. Epub 2023 Aug 24 https://pubmed.ncbi.nlm.nih.gov/?term=Alvarado-Vazquez+PA&cauthor_id=37615432
Luciana Kase Tanno dedicated her career to epidemiology research to support public health and preventive actions, more particularly focusing on hypersensitivity conditions such as anaphylaxis. Leveraging a detailed academic and evidence-based action plan, her work helped in reviewing the current International Classification of Diseases to provide greater visibility to allergic and hypersensitivity conditions. Her efforts and commitment will further ensure that patients may benefit from the best management strategy throughout the world.
Kase Tanno et al, Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases 11.” J Allergy Clin Immunol. 2019 Sep;144(3):627-633. doi: 10.1016/j.jaci.2019.05.013. Epub 2019 Jun 20. https://pubmed.ncbi.nlm.nih.gov/31229269/
Dorra Gharbi’s research focuses on aerobiology, air quality and environmental health. Her transdisciplinary work is enhancing our understanding of how climate, environmental exposures (aeroallergens) and intrinsic factors intersect to impact respiratory health outcomes. Her efforts to investigate a phenomenon in a specific setting “allergenic pollen-producing trees within the context of urban green infrastructure in South African cities”, to inform a wider inquiry regarding the health risk for the South African population, as well as the management thereof in a sustainable implementation framework. The outcome of this research opens the possibility of designing early warning systems to predict community-level surges in poor respiratory health outcomes and be able to provide allergy management plans to prevent allergic reactions.
Gharbi, D., Neumann, F.H., Cilliers, S. et al. Allergenic tree pollen in Johannesburg and Cape Town as a public health risk: towards a sustainable implementation framework for South African cities. Discov Sustain 4, 32 (2023). https://doi.org/10.1007/s43621-023-00151-9
About the Stallergenes Greer Foundation
The Stallergenes Greer Foundation, under the aegis of the Fondation de France, is a non-profit foundation whose aim is to build healthier futures for all. The Stallergenes Greer Foundation pursues a comprehensive approach calling for “the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment”, as defined by the One Health initiative.
About the Fondation de France
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity and translate them into effective actions of general interest. With close to 1,000 hosted foundations, the Fondation de France supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527622781/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
